Philippe Moreau

Has grant

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Medico-economic assessment of TEP-FDG use in patients affected by multiple myeloma (patients aged < 65 years, protocol IFM 2009-01)

Open Date: 2010-06-01

Close Date: 2012-06-01

Articles (11)

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Jo Caers

BELGIUM

View details

Wojciech Maciej Legiec

head physician

POLAND

View details

Artur Jurczyszyn

POLAND

View details

Reuben Benjamin

Consultant Haematologist and Clinical Senior Lecturer

King's College Hospital

UNITED KINGDOM

View details

hareth nahi

Karolinska University Hospital

SWEDEN

View details

Maxime Jullien

Nantes University Hospital

FRANCE

View details

Aurore Perrot

Professor of Hematology

Université Paul Sabatier

FRANCE

View details

Niels W. C. J. van de Donk

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Philippe Moreau

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (11)

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study.

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Extramedullary disease in multiple myeloma: a systematic literature review

T-cell redirecting bispecific antibodies in multiple myeloma: a revolution?

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.

ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma.

Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant.

Collaborators (8)

Jo Caers

Wojciech Maciej Legiec

Artur Jurczyszyn

Reuben Benjamin

hareth nahi

Maxime Jullien

Aurore Perrot

Niels W. C. J. van de Donk

Make your next move.